BRAF and metastatic malignant neoplasm in the lymph nodes: CtDNA analysis of patient ID12 with a BRAF mutation showed a high MAF level (≥1%) at baseline with no longer detectable MAF and radiologically completely regressed lung and lymph node metastases, but new bone lesions developed during targeted therapy.